INS and type 2 diabetes mellitus: Rimonabant was able to reduce appetite thereby promoting weight loss, improved lipid profiles, and enhanced insulin sensitivity, potentially lowering the risk of type 2 diabetes (Bronander and Bloch, 2007; Thornton-Jones et al., 2006).